Islamabad, Pakistan – On September 8, Shanghai MicroPort Medical (Group) Co ("MicroPort®") announced that its in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") received approval from the Drug Regulatory Authority of Pakistan (“DRAP”).
Firehawk® is MicroPort®'s third generation drug-eluting stent ("DES"), used for the treatment of coronary artery stenosis and occlusion after Firebird® Rapamycin-Eluting Coronary Stent and Firebird2® Rapamycin-Eluting Coronary CoCr Stent. As the world's lowest drug dosage stent, Firehawk® combines the merits of bare metal stents and DES. It adopts unique in-groove abluminal coating design and target-eluting technique, which allow Firehawk® to achieve the same clinical efficacy with significantly low drug loading, benefiting vascular early healing.
Pakistan is the sixth most populous country in the world. Pakistani population has one of the highest risks of coronary heart disease in the world. In Pakistan, 30 to 40 percent of all deaths can be attributed to cardiovascular diseases. The coronary heart disease death in Pakistan has reached about 200,000 per year. With Firehawk®'s regulatory approval in Pakistan, MicroPort® will offer more ideal solutions to local patients.